Skip to main content

Market Overview

ROCE Insights For Evofem Biosciences


In Q4, Evofem Biosciences (NASDAQ:EVFM) posted sales of $168.00 thousand. Earnings were up 37.07%, but Evofem Biosciences still reported an overall loss of $35.85 million. In Q3, Evofem Biosciences brought in $278.00 thousand in sales but lost $26.16 million in earnings.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Evofem Biosciences's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Evofem Biosciences posted an ROCE of -26.62%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Evofem Biosciences's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q4 Earnings Insight

Evofem Biosciences reported Q4 earnings per share at $-0.5/share, which did not meet analyst predictions of $-0.36/share.


Related Articles (EVFM)

View Comments and Join the Discussion!

Posted-In: BZI-ROCEEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at